Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.

Date publication

novembre 2021

Journal

European journal of heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Quinn CM, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, der Meer PV, Weir M, Pitt B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34800079

Résumé

In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K ) binder, may improve serum K levels and adherence to RAASi.

Mots clés

adherence, heart failure, hyperkalaemia, mineralocorticoid receptor antagonists, patiromer, potassium, renin-angiotensin-aldosterone system inhibitors, trial design

Référence

Eur J Heart Fail. 2021 Nov 20;: